ABBV AbbVie
- 161.720
- -0.920-0.57%
- 161.910
- +0.190+0.12%
AbbVie News
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)
Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects
AbbVie Analyst Ratings
Barclays Adjusts Price Target on AbbVie to $187 From $195
Analysts' Top Healthcare Picks: AbbVie (ABBV), Wave Life Sciences (WVE)
Buy Rating Affirmed: AbbVie's Strong Performance and Positive Growth Outlook
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)
Hold Rating on AbbVie Amid Revenue Decline and Profitability Concerns
AbbVie (ABBV) Gets a Buy From Piper Sandler
Hold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie Acquisition
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
AbbVie (ABBV) Gets a Buy From Barclays
Buy Rating on AbbVie: Resilient Humira Market Position and Promising Pipeline Outlook
Analysts Conflicted on These Healthcare Names: Conmed (CNMD), AbbVie (ABBV) and Nurix Therapeutics (NRIX)
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Universal Health (UHS) and Teladoc (TDOC)
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV)
Maintaining Hold Rating on Landos Biopharma Amid Acquisition by AbbVie and Limited Upside Potential
AbbVie Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
Analysis
Price Target
No Data
